Myriad Genetics Inc
MYGN3.903USD
-0.007-0.18%
Market hours （ET）Quotes delayed by 15 min
359.87MMarket Cap
LossP/E TTM
More Details of Myriad Genetics Inc Company
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.
Company Info
Ticker SymbolMYGN
Company nameMyriad Genetics Inc
IPO dateOct 06, 1995
CEOMr. Samraat S. (Sam) Raha
Number of employees2700
Security typeOrdinary Share
Fiscal year-endOct 06
Address322 North 2200 West
CitySALT LAKE CITY
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code84116
Phone18015843600
Websitehttps://myriad.com/
Ticker SymbolMYGN
IPO dateOct 06, 1995
CEOMr. Samraat S. (Sam) Raha
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
221.65K
-11.52%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+60.47%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
128.68K
+56.61%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+64.34%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
45.88K
-46.96%
Ms. S. Louise Phanstiel, CPA
Ms. S. Louise Phanstiel, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Matt Scalo
Mr. Matt Scalo
Investor Relations
Investor Relations
--
--
Ms. Jennifer Fox
Ms. Jennifer Fox
Chief Legal Officer
Chief Legal Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
221.65K
-11.52%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+60.47%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
128.68K
+56.61%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+64.34%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Hereditary Cancer
86.30M
44.05%
Prenatal
49.30M
25.17%
Pharmacogenomics
31.00M
15.82%
Tumor Profiling
29.30M
14.96%
By RegionUSD
Name
Revenue
Proportion
United States
181.60M
92.70%
Rest of world
14.30M
7.30%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Hereditary Cancer
86.30M
44.05%
Prenatal
49.30M
25.17%
Pharmacogenomics
31.00M
15.82%
Tumor Profiling
29.30M
14.96%
Shareholding Stats
Updated: Thu, May 15
Updated: Thu, May 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
15.02%
The Vanguard Group, Inc.
10.04%
State Street Global Advisors (US)
5.72%
Disciplined Growth Investors, Inc.
5.14%
Wellington Management Company, LLP
4.98%
Other
59.10%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
15.02%
The Vanguard Group, Inc.
10.04%
State Street Global Advisors (US)
5.72%
Disciplined Growth Investors, Inc.
5.14%
Wellington Management Company, LLP
4.98%
Other
59.10%
Shareholder Types
Shareholders
Proportion
Investment Advisor
47.03%
Investment Advisor/Hedge Fund
31.99%
Hedge Fund
18.89%
Research Firm
3.85%
Individual Investor
3.25%
Pension Fund
1.35%
Bank and Trust
0.41%
Sovereign Wealth Fund
0.07%
Insurance Company
0.04%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
514
98.55M
106.92%
-3.88M
2025Q1
527
99.14M
107.57%
-4.54M
2024Q4
516
96.89M
106.12%
-1.41M
2024Q3
505
95.02M
104.61%
-5.50M
2024Q2
486
96.79M
106.52%
-6.22M
2024Q1
460
98.19M
108.68%
+613.48K
2023Q4
464
93.46M
105.77%
+2.70M
2023Q3
471
86.01M
104.78%
-3.73M
2023Q2
480
84.60M
103.32%
-6.34M
2023Q1
483
85.87M
105.37%
-2.69M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
13.85M
15.02%
-471.44K
-3.29%
Mar 31, 2025
The Vanguard Group, Inc.
10.62M
11.52%
+47.03K
+0.44%
Mar 31, 2025
State Street Global Advisors (US)
5.27M
5.72%
-256.92K
-4.65%
Mar 31, 2025
Disciplined Growth Investors, Inc.
4.73M
5.14%
+2.18M
+85.16%
Mar 31, 2025
Wellington Management Company, LLP
4.59M
4.98%
-1.41M
-23.52%
Mar 31, 2025
Millennium Management LLC
4.07M
4.41%
-275.67K
-6.34%
Mar 31, 2025
EARNEST Partners, LLC
3.98M
4.31%
+5.69K
+0.14%
Mar 31, 2025
Glenview Capital Management, LLC
3.90M
4.23%
-257.77K
-6.20%
Mar 31, 2025
D. E. Shaw & Co., L.P.
2.52M
2.74%
+702.80K
+38.62%
Mar 31, 2025
SEI Investments Management Corporation
2.42M
2.62%
-110.27K
-4.36%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Global X Genomics & Biotechnology ETF
0.6%
WisdomTree BioRevolution Fund
0.6%
Invesco NASDAQ Future Gen 200 ETF
0.57%
Invesco S&P SmallCap Health Care ETF
0.35%
Federated Hermes MDT Small Cap Core ETF
0.3%
Strategas Global Policy Opportunities ETF
0.21%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.18%
SPDR S&P Biotech ETF
0.15%
Inspire Small/Mid Cap ESG ETF
0.12%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.09%
View more
Global X Genomics & Biotechnology ETF
Proportion0.6%
WisdomTree BioRevolution Fund
Proportion0.6%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.57%
Invesco S&P SmallCap Health Care ETF
Proportion0.35%
Federated Hermes MDT Small Cap Core ETF
Proportion0.3%
Strategas Global Policy Opportunities ETF
Proportion0.21%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion0.18%
SPDR S&P Biotech ETF
Proportion0.15%
Inspire Small/Mid Cap ESG ETF
Proportion0.12%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.09%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
